Skip global navigation and go to header navigation

Skip global navigation and read the article

Skip global navigation and go to local navigation

Skip global navigation and go to footer navigation



Home > Corporate Profile > Company Outline

Company Outline


Company Outline

Company Name Zeria Pharmaceutical Co., Ltd. (Zeria Shinyaku Kogyo K.K.)
Headquarters 10-11, Nihonbashi Kobuna-cho, Chuo-ku, Tokyo 103-8351, Japan
Tel. +81-3-3663-2351
Established December 1955
Representative President & COO Mitsuhiro Ibe
Business Operations 1) Manufacture, sales, import and export of pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals and reagents; 2) Manufacture, sales, import and export of cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, analytical equipment; and 3) Activities related to the items described in 1) and 2)
Paid-in Capital ¥6,593,398,500
No. of Employees 1,871 (All group employees, as of July 1, 2018)
Board of Directors Chairman & CEO Sachiaki Ibe
President & COO Mitsuhiro Ibe
Executive Vice President Hirokazu Endo
Managing Director Makoto Kishimoto
Directors of the Board Tetsuo Komori
Kikuo Nomoto
Hiroki Kato
Yoshihiro Hiraga
Katsuyuki Ishii
Toshiaki Kawagoe
Mitsuyuki Yoshijima
Kenji Kusano
Audit & Supervisory
Board Members(Full-time)
Shigeya Furuhata
Koujirou Takami
Audit & Supervisory
Board Members(Outside)
Yukiko Naka
Hiroshi Wakabayashi

Company History

1955.12 Zeria Yakusho Kenkyusho Co., Ltd. was established in Tokyo (capital: ¥3 million).
1959.11 Launched Chondroitin, a pharmaceutical product.
1964.12 Launched Chondroitin ZS Tablets, a remedy for arthralgia and lumbalgia.
1968 Launched Hepalyse Tablets.
1970.5 Changed name to Zeria Pharmaceutical Co., Ltd.
1975.4 Saitama Plant started operations.
1979.3 Launched New Hepalyse, a nutrient tonic for physical fatigue and exhaustion.
1983.10 Established Central Research Laboratories in Saitama.
1986.4 Developed and launched Avitene, an absorbable topical hemostat in-licensed from U.S.-based Alcon Laboratories, Inc.
1987.11 Launched WithOne, an herbal laxative.
1988.11 Tsukuba Plant started operations.
1990.9 Launched Acinon Capsules 150, an anti-ulcerant in-licensed from U.S.-based Eli Lilly and Company and co-developed with Eli Lilly Japan K.K.
1991.9 Launched Ancer 20 Injection, an anti-leukopenia after radiotherapy.
1993.9 Launched Peon Tablets 80, an oral non-steroidal anti-inflammatory co-developed with Nippon Chemiphar Co., Ltd.
1994.4 Launched Landel Tablets 10/20, a long-acting calcium channel blocker co-developed with Nissan Chemical Industries, Ltd.
1994.10 Launched Promac Granules 15%, a zinc containing anti-ulcerant.
1996.2 Launched New Hepalyse Plus, a nutrient tonic for physical fatigue and exhaustion.
1998.12 On December 22, listed on the Second Section of the Tokyo Stock Exchange.
Introduced new company logo and symbol mark.
1999.2 Started a new distribution system outsourced to ITOCHU Corporation and its affiliate,
Superlex Co., Ltd.
2000.3 On March 1, listed on the First Section of the Tokyo Stock Exchange.
2004.1 Concluded a licensing agreement with Tillotts Pharma AG in Switzerland for the development, manufacturing and marketing rights to Asacol for IBD in Japan.
2005.7 Launched New Hepalyse Drink, a nutrient tonic for physical fatigue and exhaustion.
2006.3 Sales of Chondroitin range of products reached ¥5 billion.
2006.7 Launched Promac D Tablets 75, a zinc containing anti-ulcerant.
2006.11 Expanded Tsukuba Plant (second phase construction).
2007.6 Launched Visiclear Tablets, an oral bowel cleansing agent for colonoscopy.
2007.11 Launched Acinon Tablets 75mg and 150mg, an H2 receptor antagonist.
2008.6 TV advertisements for Chondroitin ZS Tablets started.
2008.10 Acquired IONA INTERNATIONAL CORPORATION and made it a wholly owned subsidiary.
2009.9 Acquired Tillotts Pharma AG and made it a wholly owned subsidiary.
2009.12 Launched Asacol Tablets 400mg, a therapeutic agent for ulcerative colitis.
2010.7 TV advertisements for New Hepalyse Drink started.
2010.9 Acquired ZPD (formerly Biofac Esbjerg A/S) and made it a subsidiary.
2011.11 Launched Hepalyse W as a beverage in the general foods category for convenience stores.
2012.1 Launched New WithOne, an herbal laxative.
2012.3 TV advertisements for New WithOne started.
2013.3 Launched Phosribbon Combination Granules, a therapeutic agent for hypophosphatemia.
2013.6 Launched Acofide Tablets 100mg, a therapeutic agent for functional dyspepsia.
2013.10 Launched Hepalyse W Hyper as a beverage in the general foods category for convenience stores.
2014.9 Launched Prefemin, a therapeutic agent for PMS
2015.6 Launched Hepalyse W Sparkling as a carbonated nutritional drink in the general foods category for convenience stores.
2015.7 Tillotts Pharma AG acquired all global rights outside the United States for Entocort from AstraZeneca.
2015.9 Acquired 49% of the shares of Pharmaceutical Joint Stock Company of February 3rd and made it a subsidiary.
2016.3 Launched Hepalyse W Premium as a beverage in the general foods category for convenience stores.
2016.3 Sales of Hepalyse range of products reached ¥10 billion.